Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 10 years. On May 5, Emily Field from Barclays lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,400 from $1,350 and maintained an Overweight rating following the first-quarter results. In a research note, the analyst stated that the company’s “strong tirzepatide momentum takes focus back to the big picture.”
Goldman Sachs, too, advises investors to concentrate on the bigger picture highlighted in the company’s Q1 earnings analysis. The firm reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,283. The firm said that the safety profile of Foundayo has been well established across 11,000 patients in Phase 3 trials, calling the stock weakness an overreaction.
In its earnings call, Eli Lilly and Company (NYSE:LLY) revised 2026 full-year revenue guidance to $82-85 billion, with the midpoint indicating 28% growth compared to 2025. The company’s non-GAAP EPS of $35.50-$37 is also higher than the previous estimate, thanks to its robust performance across major therapeutic areas. No wonder the company is one of the stocks with the best earnings growth for the next decade.
Eli Lilly and Company (NYSE:LLY) is an Indiana-based company specializing in human pharmaceutical products. Founded in 1876, the company offers products for cardiometabolic health, oncology, immunology, and migraine prevention.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
